Patients with chromophobe RCC are more likely to experience complete recovery of kidney function after radical nephrectomy, and this is associated with better survival. While uncommon, complete ...

A new analysis of U.S. military personnel included Black, White, and Hispanic adults newly diagnosed with primary stage I-III RCC between 1998 and 2014. Hispanic and White patients had similar rates ...

—Robotic and laparoscopic techniques showed advantages over open surgery, including fewer complications, shorter hospital stays, and lower mortality in people with renal cancer. Renal cell carcinoma ...

A laparoscopic nephrectomy involves the removal of one kidney through a series of small incisions with a special tool called a laparoscope. It’s an option to treat kidney cancer and other conditions ...

In a radical nephrectomy, a surgeon removes your entire kidney and the surrounding tissue. It’s a common and effective surgery that aims to cure kidney cancer before it spreads. “Radical” is the term ...

Show More Hiten D. Patel and Mohamad E. Allaf, Johns Hopkins University School of Medicine, Baltimore, MD; Jose A. Karam, The University of Texas MD Anderson Cancer Center, Houston, TX. Despite the ...

Background. A 57-year-old woman presented to the emergency department at a community hospital with a 2-month history of fatigue and right-sided flank and abdominal pain. Noncontrast CT of the abdomen ...

Background: Two randomized trials published in 2001 established cytoreductive nephrectomy (CyNx) for patients (pts) with metastatic renal carcinoma (mRCC) as a treatment standard in the cytokine era ...

January 10, 2008 — Most patients found to have a small kidney tumor, between 2 and 4 cm in size, have the whole kidney removed. However, new findings suggest that for younger patients a partial ...

In a partial nephrectomy, a portion of your kidney is surgically removed, sparing some function in that kidney. This surgery is most often performed in instances of a small tumor localized to the ...

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, for the adjuvant treatment of ...